Insulin-secretagogue, antihyperlipidemic and other protective effects of gallic acid isolated from Terminalia bellerica Roxb. in streptozotocin-induced diabetic rats

Latha, R; Daisy, P.

doi:10.1016/j.cbi.2010.11.005

Cited by 209 publications

(107 citation statements)

References 31 publications

Supporting

Mentioning

101

Contrasting

Unclassified

Order By: Relevance

“…The hydrophobic interactions were ascribed to the N-methyl group of rosiglitazone, which interacts with Cys285, Leu353, and Met364 (Figure 2A). The interaction profile for rosiglitazone in the PPARγ binding domain is consistent with a previous report [22]. However, the new analog, LASSBio-1772, lost the electrostatic interaction with PPARγ and was unable to perform hydrogen bonding with the receptor.…”

Section: Somatosensory Testing -Heat Withdrawal and Allodyniasupporting

confidence: 90%

Novel Partial Agonist of PPAR-Gamma for Treatment of Diabetic Neuropathy in Rats

Lima¹,

Trachez²,

Araujo³

et al. 2014

J Diabetes Metab 2013

View full text Add to dashboard Cite

This work describes a novel ligand for peroxisome proliferator-activated receptor gamma (PPARgamma) and its hypoglycemic and analgesic activity in a murine model of diabetes-induced neuropathic pain. The molecular recognition of LASSBio-1772 by a PPARgamma binding domain showed that the compound is a partial agonist. Four weeks after male Wistar rats received a single intravenous injection of streptozotocin (STZ, 60 mg/kg), plasma glucose levels were increased from 92.5 ± 3.7 to 465.0 ± 21.6 mg/dL (P < 0.01) and serum insulin was reduced from 66.8 ± 7.8 to 25.5 ± 5.6 pmol/L (P<0.01). Diabetic animals were then, treated with either vehicle or LASSBio-1772 (50 mg/kg, i.p.) daily for 7 days. LASSBio-1772 significantly reduced blood glucose levels to 242.0 ± 55.1 mg/dL (P<0.05) and increased insulin levels to 58.7 ± 14.8 pmol/L (P<0.05), indicating the hypoglycemic activity of this compound. LASSBio-1772 also reduced the elevated triglyceride levels induced by STZ treatment from 74.1 ± 8.6 to 34.0 ± 6.3 mg/dL (P<0.01). LASSBio-1772 could reduce serum glucose levels via increased insulin levels and potentially improve insulin sensitivity. Neuropathy was detected after four weeks of STZ-induced diabetes, with reduced thermal heat withdrawal latency from 11.7 ± 0.1 to 7.1 ± 0.2 s (P<0.01) and paw withdrawal threshold from 37.5 ± 2.1 to 29.9 ± 1.1 g (P<0.05) indicating the establishment of hyperalgesia and allodynia. LASSBio-1772 treatment restored both measures to non-diabetic values (12.2 ± 0.4 s and 34.5 ± 1.5 g). In conclusion, treatment with LASSBio-1772, a partial PPARgamma agonist, decreased hyperglycemia and neuropathic pain induced by diabetes. PPARgamma stimulation by LASSBio-1772 could prevent inflammation and inhibit both peripheral and central sensitization.

show abstract

Section: Somatosensory Testing -Heat Withdrawal and Allodyniasupporting

confidence: 90%

Novel Partial Agonist of PPAR-Gamma for Treatment of Diabetic Neuropathy in Rats

Lima¹,

Trachez²,

Araujo³

et al. 2014

J Diabetes Metab 2013

View full text Add to dashboard Cite

show abstract

“…Hence, EAF was further exploited for isolation, which led to the isolation of gallic acid (GA), a phenolic acid and rutin (RU), a flavonoid glycoside. GA was isolated as a white colored compound and RU as a yellowish amorphous powder, which were characterized as GA and RU based on their melting point and spectroscopic (IR, 1 H, 13 C Nuclear magnetic resonance (NMR) and Mass Spectrometry (MS)) data (Latha & Daisy, 2011;Abdullah et al, 2008).…”

Section: Extraction and Isolationmentioning

confidence: 99%

Hypoglycaemic effect ofMelothria heterophyllain streptozotocin-induced diabetic rats

Mondal

Maity

Pal

2012

Pharmaceutical Biology

View full text Add to dashboard Cite

“…This polyphenol is even more effective than ascorbic acid to prevent lipid peroxidation (15). Also, it was reported that GA shows antihyperglycemic and antihyperlipidemic activities (18).…”

Section: Introductionmentioning

confidence: 99%

Hepato-renal protective effects of gallic acid and p-coumaric acid in nicotinamide/streptozotocin-induced diabetic rats

Abdel-Moneim

El‐Twab

Ashour

et al. 2016

IJB

View full text Add to dashboard Cite

The goal of diabetes treatment is primarily to save life and alleviate symptoms and secondary to prevent long-term diabetic complications resulting from hyperglycemia. Thus, our present investigation was designed to evaluate the hepato-renal protective effects of gallic acid and p-coumaric acid in nicotinamide/streptozotocin (NA/STZ)-induced diabetic rats. Experimental type 2 diabetes was induced by a single intraperitoneal (i.p.) injection of STZ (65 mg/kg b.wt.), after 15 min of i.p. injection of NA (120 mg/kg b.wt.). Gallic acid and p-coumaric acid were orally administered to diabetic rats at a dose of 20, 40 mg/kg b.wt./day, respectively, for 6 weeks. Body weight, serum glucose, protein profile, liver function enzymes and kidney function indicators was assayed. Treatment with either gallic acid or p-coumaric acid significantly ameliorated the elevated levels of glucose, alanine aminotransferase (ALT), aspartate aminotransferase (AST), urea and uric acid. Both compounds were also found to restore total protein, albumin, and globulin as well as body weight of diabetic rats to near normal values. It can conclude that both gallic acid and p-coumaric acid have potent hypoglycemic and hepato-renal protective effects in diabetic rats. Therefore, our results suggest promising hypoglycemic agents that can attenuate the progression of diabetic hepatopathy and nephropathy.

show abstract

Insulin-secretagogue, antihyperlipidemic and other protective effects of gallic acid isolated from Terminalia bellerica Roxb. in streptozotocin-induced diabetic rats

Cited by 209 publications

References 31 publications

Novel Partial Agonist of PPAR-Gamma for Treatment of Diabetic Neuropathy in Rats

Novel Partial Agonist of PPAR-Gamma for Treatment of Diabetic Neuropathy in Rats

Hypoglycaemic effect ofMelothria heterophyllain streptozotocin-induced diabetic rats

Hepato-renal protective effects of gallic acid and p-coumaric acid in nicotinamide/streptozotocin-induced diabetic rats

Contact Info

Product

Resources

About